Argenx Se · EURONEXT:ARGX
Argenx — Q4 2023 Earnings Presentation
15 slides from Argenx's earnings presentation, Feb 29, 2024
Slide 1: Reaching Patients through Immunology Innovation
Reaching Patients through Immunology Innovation F Y / 4 Q 2 0 2 3 E A R N I N G S C A L L | F E B R U A R Y 2 9 , 2 0 2 4
Slide 2: Forward Looking Statements
Forward Looking Statements • This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter
Slide 3: Our Innovation Horizons
PFS in development 15 indications in development by 2025 ITP MAA filed CIDP sBLA accepted PDUFA June 21, 2024 ARGX-109 $1.2B in gMG revenue in 2023 (Anti-IL-6) ARGX-213 (Anti-FcRn) ARGX-220 ARGX-121 Empasiprubart POC established in MMN Trials in DGF and DM ARGX-119 Phase 1b/2a trials in CMS and ALS
Slide 4: Maximizing the VYVGART Opportunity
Maximizing the VYVGART Opportunity Upcoming Regulatory Decisions Expanding MG Opportunity Launch Strategy Success ITP CIDP March 2024 decision Japan (VYVGART IV) PDUFA June 21, 2024 Geography US (VYVGART SC) Presentation 4
Slide 5: This is Just the Beginning
This is Just the Beginning 5 Myasthenia Gravis Chronic Inflammatory Demyelinating Polyneuropathy Expected 2024 PoC study readouts ITP Launched 2022 FDA PDUFA June 21, 2024 Japan Regulatory Decision Q1 2024 TED 100K IMNM 6K Sjogren’s 330K PC-POTS 500K Beyond 2024 PoC studies BP 52K LN 40K MN 80K AAV
Slide 6: Empasiprubart and ARGX-119
Empasiprubart Targeting Complement Upstream ARGX-119 Enhancing the NMJ Natural history studies ongoing in both MMN and CMS to better understand real-world experience of patients Optimal recycling pH and Ca2+ switch No effector function Full Phase 2 MMN data expected in 2024 Agonist to MuSK No effect
Slide 7: Pipeline Growth Driven By Immunology Innovation Program
Efgartigimod ARGX-119 Empasiprubart Internal Value Creation External Value Creation OncoVerity (Cusatuzumab) LEO (ARGX-112) ARGX-109 AbbVie (ARGX-115) ARGX-118 Agomab (ARGX-114) Dualyx Pipeline Growth Driven By Immunology Innovation Program ARGX-213 ARGX-121 ARGX-220 Expanding Technical Capabilities
Slide 8: Fourth Quarter 2023 Revenue
Fourth Quarter 2023 Revenue Product Net Sales: 2023 Full Year with $1,191 million and Q4 2023 with $374 million 21 75 131 173 218 269 329 374 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q4 2023 Q3 2023 Q2 2022 Q1 +257% (+54) +75% (+56) +32% (+42) +26% (+45) +23% (+51) +22% (+60) +14% (+45) (in millions of
Slide 9: 2023 Financial Summary and 2024 Financial Guidance
2023 Financial Summary 2024 Financial Guidance ($B) 2024 Cash burn(1) ~ 0.5 Combined R&D and SG&A expenses < 2.0 (1) - Cash burn is equal to the decrease in our cash, cash equivalents and current financial assets Three months ended Twelve months ended (in millions of $) December 31 December 31 2023
Slide 10: Continuing to drive transformational outcomes for patients
Continuing to drive transformational outcomes for patients Alexis, VYVGART Patient Reaching new gMG patients with VYVGART Leveraging MG know-how into future indications Maximizing value creation and patient impact
Slide 11: Strong Commercial Execution in 2023
Strong Commercial Execution in 2023 21% 2023 CAGR $1.2B Global Product Revenue G R O W T H * As of Q3 2023 Financial Results B O L S T E R E D B Y R E A L - W O R L D E X P E R I E N C E MSE 45% 55% patients from orals >6,000* Global VYVGART Patients E A R L I E R L I N E P A T I E N T S 25% YoY in
Slide 12: Innovation Builds Autoimmune Market Opportunities
Innovation Builds Autoimmune Market Opportunities Growing MG Market gMG Patients on VYVGART Current VYVGART TAM Expanding VYVGART TAM Growing VYVGART Share US RoW argenx markets (exc. China) Global Growing VYVGART share • US: VYVGART Hytrulo J-Code • PFS development • Added to China NRDL Expanding V
Slide 13: We Aim to Address the Unseen Suffering in CIDP
CONFIDENTIAL FOR INTERNAL USE ONLY. © 2023 argenx. We Aim to Address the Unseen Suffering in CIDP ≤20% of patients achieve remission on current SOC (CDAS=2)* >50% of patients are dissatisfied with their symptom burden** >42K treated CIDP patients in US & ROW argenx markets (ex-China)*** * Gorson KC,
Slide 14: Generating Disease Awareness
Caitlin, MG patient Generating Disease Awareness Long -term commitment to repeatable, sustainable and comprehensive value creation Maximizing patient impact through our commercial organization Driving Innovation on Patient Experience Providing Broad and Simple Access Elevating Expectations for Treat
Slide 15: We are on a bold mission
We are on a bold mission Humility Innovation Excellence Co-Creation Empowerment 15